News: Portfolio 2006

Amorcyte Secures Additional Funding To Expand Clinical Program In Cardiovascular Cell Therapy

PA Early Stage joins Colt Ventures in expanding Amorcyte's product program

HACKENSACK, New Jersey October 23, 2006 Amorcyte, Inc. (Amorcyte), a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, has secured additional funding to complete its first phase I trial and pursue additional cell therapy opportunities for cardio and vascular diseases.


The financing was placed by PA Early Stage Partners, a family of venture capital funds founded in 1997, headquartered in Wayne, Pennsylvania, and investing in early stage life sciences and technology companies. This funding adds to the $4.2 million first round Amorcyte announced in June led by Colt Ventures.